Multitarget Drug Design for Cardiovascular Disease: Bridging Chemistry and Medicine
This review provides an overview of recent advances in the development of multitarget drugs (MTDs) for cardiac diseases, with a particular focus on emerging molecular scaffolds and their pharmacological properties. We discuss the fundamental principles of cardiac polypharmacology and multitarget drug design, highlighting key compound classes, such as 1,4-benzothiazepines, 1,4-dihydropyridines (DHPs), and polyphenol derivatives. Particular emphasis is placed on the relationship between the structural features and the pharmacological activity, efficacy, and therapeutic potential of these compounds.
Authors
- Gyuzel Yu. Mitronova (ORCID: https://orcid.org/0000-0003-4376-6981)
- Stephan E. Lehnart (ORCID: https://orcid.org/0000-0002-8115-3513)
- Constanze Schmidt (ORCID: https://orcid.org/0000-0001-5897-237X)
- Vladimir N. Belov (ORCID: https://orcid.org/0000-0002-7741-4653)
Institutions
- Fraunhofer Institute for Translational Medicine and Pharmacology (DE)
- Universitätsmedizin Göttingen (DE)
- German Centre for Cardiovascular Research (DE)
- Max Planck Institute for Multidisciplinary Sciences (DE)
- University of Göttingen (DE)
Publication Details
- Journal
- ChemMedChem
- Published
- 2026-10-13
- DOI
- https://doi.org/10.1002/cmdc.70506
- Primary Topic
- Computational Drug Discovery Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.00